GBA3 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The GBA3 gene encodes a member of the glycoside hydrolase family, specifically a lysosomal glucocerebrosidase enzyme. Also known as β-glucosidase or glucosidase beta 3, this enzyme catalyzes the hydrolysis of glycolipids and is genetically distinct from the well-known GBA gene (glucosylceramidase). GBA3 has been implicated in Parkinson's disease risk and participates in cellular lipid metabolism.
| Attribute |
Value |
| Gene Symbol |
GBA3 |
| Official Full Name |
Glucosidase beta 3 |
| Chromosomal Location |
4p15.2 |
| Gene ID |
57733 |
| UniProt ID |
Q9Y5K2 |
| Protein Class |
Glycoside hydrolase, family 1 |
- Official Name: Glucosidase beta 3
- Alternate Names: β-glucosidase, glucosylceramidase 2, CBGL1
- HGNC ID: 24523
GBA3 encodes a 556-amino acid protein with:
- Signal Peptide: N-terminal targeting sequence for lysosomal localization
- Propeptide: Cleaved during activation
- catalytic Domain: Contains the active site for glucosidase activity
- Carbohydrate-Binding Domain: For substrate recognition
The enzyme is a homodimer in its active form, requiring optimal pH 4.5-5.5 for activity.
GBA3 hydrolyzes:
- Glucosylceramide → Glucose + Ceramide
- Glucosylsphingosine (lyso-GL1) → Glucose + Sphingosine
- Other glycolipids: Various β-glucosidic bonds
Unlike GBA (acid β-glucosidase), GBA3 shows:
- Broader substrate specificity
- Activity toward glucosylceramide and glucosylsphingosine
- Lower catalytic efficiency toward glucosylceramide
- Potential activity toward isoflavone glucosides (genistein, daidzein)
GBA3 is expressed in:
- Liver: Hepatocytes (highest expression)
- Kidney: Renal tubules
- Small Intestine: Enterocytes
- Brain: Lower expression, various regions
- Immune Cells: Monocytes, macrophages
- Placenta: Trophoblastic cells
Lysosomal localization is mediated by the mannose-6-phosphate recognition system.
GBA3 participates in glycosphingolipid catabolism:
- Sphingolipid Turnover: Breakdown of glucosylceramide for recycling
- Ceramide Generation: Provides ceramide for signaling molecules
- Membrane Composition: Maintains proper lipid bilayer composition
- Cell Homeostasis: Prevents accumulation of glycosphingolipids
Unique to GBA3, the enzyme can hydrolyze:
- Genistein glucoside (daidzein)
- Daidzin
- Glycitin
This suggests a role in dietary isoflavone metabolism, particularly relevant for Asian populations with high soy intake.
In the brain, GBA3 may:
- Process glucosylceramide in neurons
- Generate ceramide for pro-survival signaling
- Interact with α-synuclein clearance pathways
The GBA gene is a well-established PD risk factor. GBA3 has also been studied:
- Genetic Association: Some GBA3 variants may modify PD risk
- Expression Changes: Altered GBA3 expression in PD brains
- Functional Impact: Reduced GBA3 activity may contribute to glycolipid accumulation
Research is ongoing to determine if GBA3 variants:
- Increase susceptibility to α-synuclein pathology
- Modify disease severity
- Influence treatment response
While GBA (not GBA3) is the primary gene causing Gaucher disease, GBA3 variants:
- May modify disease severity in GBA carriers
- Could provide compensation for GBA deficiency
- Are being studied for therapeutic potential
- Type 2 Diabetes: Some studies link GBA3 variants to glucose metabolism
- Liver Disease: Potential role in glycolipid metabolism in hepatocytes
- Isoflavone Response: May influence response to soy-based therapies
GBA3 interacts with:
- GBA (glucosylceramidase) - Paralogs
- GBA2 (non-lysosomal glucosylceramidase)
- ASM (acid sphingomyelinase)
- GALC (galactocerebrosidase)
- LAMP1, LAMP2 (lysosomal membrane proteins)
- CTSB, CTSD (cathepsins)
- GLA (α-galactosidase A)
- Ceramide and its metabolites
- Sphingosine-1-phosphate
- Glucosylceramide
Several SNPs in GBA3 have been studied:
- rs2010963: In 5'UTR, affects expression
- rs4556890: In coding region
- rs1054892: Missense variant
- rs2234246: Associated with enzyme activity
- rs3743548: In regulatory region
- Various rare variants with unknown function
- Different allele frequencies across populations
- Positive selection in some East Asian populations (possibly due to isoflavone metabolism)
- Knockout mice: Gba3 knockout mice are viable
- Zebrafish models: For developmental studies
- In vitro expression: HEK293, COS cells
- Yeast models: For enzymatic studies
- Substrates: Fluorescent glucosylceramide analogs
- Inhibitors: Specific inhibitors being developed
- Antibodies: For protein detection
- Recombinant proteins: For structural studies
| Approach |
Target |
Status |
| Enzyme replacement |
GBA3 activity |
Research |
| Small molecule activators |
Increase activity |
Preclinical |
| Gene therapy |
Restore expression |
Research |
| Substrate reduction |
Reduce substrate burden |
Research |
Understanding GBA3 may help:
- Explain variability in GBA-associated PD
- Develop targeted therapies
- Identify biomarkers for risk stratification
GBA3 encodes a lysosomal β-glucosidase with roles in glycolipid metabolism and potential implications for Parkinson's disease. While less studied than its paralog GBA, this enzyme contributes to:
- Glucosylceramide and glucosylsphingosine catabolism
- Isoflavone metabolism (unique function)
- Cellular lipid homeostasis
Further research is needed to clarify GBA3's role in neurodegeneration and explore its therapeutic potential.